Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.

  title={Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.},
  author={Stephan A. Veltkamp and Robert S. Jansen and Sophie Callies and Dick Pluim and Carla M Visseren-Grul and Hilde Rosing and Susanne Kloeker-Rhoades and Valerie A M Andre and Jos H. Beijnen and Christopher A. Slapak and Jan H. M. Schellens},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  volume={14 11},
PURPOSE To determine the toxicity, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral gemcitabine (2',2'-difluorodeoxycytidine; dFdC) in patients with cancer. EXPERIMENTAL DESIGN Patients with advanced or metastatic cancer refractory to standard therapy were eligible. Gemcitabine was administered p.o. starting at 1 mg once daily using dose escalation with three patients per dose level. Patients received one of two dosing schemes: (a) once daily dosing… CONTINUE READING
20 Citations
36 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 20 extracted citations


Publications referenced by this paper.
Showing 1-10 of 36 references

Gemcitabine metabolite , 2 ¶ , 2 ¶ - difluorodeoxyuridine ( dFdU ) , can be phosphorylated and incorporated into nucleic acids [ abstract # 1541 ]

  • SA Veltkamp, van Eijndhoven MAJ, D Pluim
  • Naunyn Schmie - debergs Arch Pharmacol
  • 2007

Phar - macokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors

  • CJ VanMoorsel, Kroep, HM Pinedo
  • Anticancer Drugs
  • 2005

Increasedcytotoxicityof 2 ¶ , 2 ¶ - difluoro - 2 ¶ - deoxycy - tidine inhumanleukemiccell - lines afterapreincubation withcyclopentenylcytosine

  • VanGennipAH VerschuurAC, LeenR, AB VanKuilenburg
  • NucleosidesNucleotides NucleicAcids
  • 2004

Similar Papers

Loading similar papers…